Clinigen Group plc Clinigen launches Japanese business

TIDMCLIN

Clinigen Group plc

18 October 2016

18 October 2016

Clinigen launches Japanese business to strengthen Asian presence

Clinigen Group plc (AIM: CLIN, 'Clinigen' or 'the Group'), the global pharmaceuticals and services group, has launched its Japanese business with the opening of an office in Tokyo, Japan. The establishment of Clinigen KK further expands the Group's presence in Asia, following Clinigen's acquisition of Link Healthcare in 2015.

Alongside the launch, Clinigen KK will transfer the Marketing Authorisation for its lead Specialty Pharmaceutical (SP) product Foscavir(R) (foscarnet sodium) back from Nobel Pharma on 1 November 2016. Nobel Pharma has been the distribution partner for Foscavir in Japan since 2011.

Foscavir is indicated to treat cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) or Cytomegalovirus viremia and cytomegalovirus disease in hematopoietic stem cell transplant (HSCT) patients. Japan was the first market where Clinigen successfully achieved a new license extension for HSCT patients in 2011.

Japan remains an important market for Foscavir with more than 2,000 patients treated annually. Clinigen will assume full marketing and distribution responsibility for Foscavir from November, to supply the product to healthcare professionals and patients across Japan.

Clinigen KK is a significant milestone for the Group in expanding its global footprint as Japan is the second largest pharmaceutical market globally. The Japanese business will allow the Group to supply and distribute both licensed and unlicensed medicines in the country, providing additional infrastructure to support Clinigen's mission to deliver the right medicine to the right patient at the right time.

Clinigen employs over 500 people globally, across 11 locations. The opening of the Japanese office further expands its international supply chain and operational network.

Shaun Chilton, Chief Executive Officer-designate, said:

"We are focused on building our market leadership positions by expanding in key geographic regions to drive sustained organic growth and better address unmet patient needs for access to critical medicines.

"The opening of our Japanese business helps support our goals and will enable us to effectively serve the Japanese market by supplying our own products, beginning with Foscavir.

"At a time when many pharmaceutical and biotechnology companies are looking for specialist partners to work with them in Asia, the opening of our Japanese office gives us more opportunities to provide customers with our global expertise combined with local knowledge."

- Ends -

Contact details

 
 Clinigen Group plc                  Tel: [phone] 
                                      495010 
 Shaun Chilton, Chief Executive 
  Officer-designate 
 Martin Abell, Chief Financial 
  Officer 
 
 Numis Securities Limited            Tel: +44 (0) 20 
                                      7260 1000 
 Michael Meade / Freddie Barnfield 
  (Nominated Adviser) 
  James Black / Tom Ballard 
  (Corporate Broking) 
 
 
 Peel Hunt LLP - Joint Broker   Tel: +44 (0) 20 
                                 7418 8900 
 James Steel / Dr Christopher 
  Golden 
 
   Instinctif Partners            Tel: +44 (0) 20 
                                  7457 2020 
 Melanie Toyne-Sewell / Jen 
  Lewis / Jayne Crook           Email: [e-mail] 
 

About Foscavir(R) (foscarnet sodium)

Foscavir(R) is licensed for the treatment of cytomegalovirus (CMV) retinitis in HIV patients, and acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in immunocompromised patients.

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time and is focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.

The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions: Idis Managed Access runs early access programs for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).

Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital medicines.

For more information, please visit www.clinigengroup.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAFFDFMWFMSEDS

(END) Dow Jones Newswires

October 18, 2016 02:01 ET (06:01 GMT)